IL-21 Expressing Mesenchymal Stem Cells for B-cell Lymphoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B-cell lymphoma, such as systemic administration of recombinant IL-21 protein or IL-21 expressing plasmid DNA, have limited ability to effectively target tumor lesions and exhibit weak anti-tumor effectiveness due to poor delivery and stability issues.
Innovation Solution
The use of IL-21 expressing mesenchymal stem cells, which are engineered to over-express IL-21 and delivered to tumor sites, providing sustained anti-tumor effects by promoting apoptosis and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of recombinant IL-21 protein or IL-21 expressing plasmid DNA is used, then anti-tumor treatment is provided, but the ability to move into tumor lesion is limited and anti-tumor effectiveness is weak
Solution Approach 1:
The patent uses mesenchymal stem cells as intermediary carriers to deliver IL-21 to tumor lesions. These stem cells naturally migrate toward tumor sites and serve as living vehicles that overcome the poor delivery capability of systemic protein or plasmid DNA administration, thereby enhancing both delivery ability and anti-tumor effectiveness
Solution Approach 2:
The mesenchymal stem cells possess inherent self-directed migration capability toward tumor lesions through chemotaxis. This self-service mechanism allows the carrier cells to automatically navigate to the target site without external guidance, improving delivery efficiency and reducing the need for complex external control systems
2Duration of action of moving object
If recombinant IL-21 protein is administered systemically, then treatment is provided, but the expression duration is limited
Solution Approach 1:
The mesenchymal stem cells provide continuous IL-21 expression at the tumor site by maintaining their differentiated state and secretory function. This continuous local production of IL-21 replaces the transient systemic protein administration, ensuring sustained anti-tumor effectiveness over extended periods
Solution Approach 2:
The stem cells are pre-engineered to constitutively express IL-21 before administration. This preliminary genetic modification ensures that once the cells reach the tumor lesion, they immediately begin producing IL-21 without requiring external stimulation, thereby extending the effective duration of action
Data Source
AI summary
Provided is a pharmaceutical composition for preventing or treating B-cell lymphoma including IL-21 expressing mesenchymal stem cells, and a treating method using the same.